Objective: Stimulation of cGMP synthesis protects cardiomyocytes against reoxygenation-induced hypercontracture. The purpose of this study was to determine whether L-arginine supplementation has a protective effect against reperfusion-induced hypercontracture and necrosis in the intact animal. Methods: Twenty-four Large-White pigs were randomized to receive either 100 mg / kg of L-arginine IV or vehicle 10 min before 48 min of coronary occlusion and 2 h of reperfusion. Hemodynamic variables, coronary blood flow and myocardial segment length changes (piezoelectric crystals) were monitored. Postmortem studies included quantification of myocardium at risk (in vivo fluorescein), infarct size (triphenyltetrazolium reaction), myocardial myeloperoxidase activity and histological analysis. Systemic, coronary vein, and myocardial cGMP concentration were measured in additional animals. Results: Administration of L-arginine had no significant effect in hemodynamics or coronary blood flow. During reperfusion, myocardial cGMP content was reduced in the LAD as compared to control myocardium (P50.02). L-Arginine increased myocardial cGMP content and caused a transient increase in plasma cGMP concentration during the initial minutes of reperfusion (P50.02). The reduction in end-diastolic segment length induced by reperfusion, reflecting hypercontracture, was less pronounced in the L-arginine group (P50.02). Infarct size was smaller in pigs receiving L-arginine (47.967.2% of the area at risk) than in controls (62.964.9%, P50.047). There were no differences between groups in leukocyte accumulation in reperfused myocardium (P50.80). Conclusion: L-Arginine supplementation reduces myocardial necrosis secondary to in situ ischemia-reperfusion by a direct protective effect against myocyte hypercontracture.
Introduction
hypercontracture and to reduce necrosis induced by transient ischemia [3, 4] . However, there is a lack of contractile Myocyte hypercontracture is a major mechanism of cell inhibitors acceptable to be safely administered to patients. death during myocardial reperfusion [1] . Hypercontracture Previous studies have shown that myocardial cGMP is the result of an excessive contractile activation during content is reduced during reperfusion following prolonged the first minutes of reperfusion caused by restoration of ischemia [5, 6] . Increasing cellular cGMP concentration 21 ATP synthesis in the presence of elevated cytosolic Ca protects isolated cardiomyocytes from reoxygenation-inconcentration [1, 2] . Transient contractile blockade during duced hypercontracture [6] [7] [8] . In the isolated rat heart, the first minutes of reperfusion, until the cell recovers increasing myocardial cGMP concentration during reperfu- 21 Ca control, has been consistently shown to prevent sion has a powerful negative inotropic effect not observed in previously nonischemic myocardium, attenuates hypercontracture, and limits necrosis [7] . We have recently described that L-arginine supple-mentation limits myocardial necrosis in the isolated rat 2.1. Study protocol heart submitted to anoxia-reoxygenation by a cGMP-dependent mechanism [8] . Although previous studies in the Animals were randomly allocated to one of two groups isolated rat heart are in general consistent with the of treatment. One group received 100 mg / kg of L-arginine hypothesis that L-arginine has a protective effect against in 100 ml infused into the femoral vein over 20 min myocardial ischemia-reperfusion injury [9] [10] [11] , the results (Harvard Syringe Infusion Pump 22, Harvard Apparatus, of in vivo studies are controversial. When these results South Natick, MA, USA). Solution pH was fitted at 7.4 have been positive, they have been associated with reduced with HCl and osmolarity ranged between 300 and 350 polimorphonuclear leukocyte (PMN) accumulation [12- mOsm. The other group (control) received the same 14]. The present study tested the hypothesis that L-arginine volume of saline. Ten min after the infusion had been supplementation, at doses used in patients [15] , protects delivered, the LAD was occluded for 48 min followed by 2 myocardium against necrosis induced by transient coronary h of reperfusion. occlusion by preventing cardiomyocyte hypercontracture occurring during the early phase of reperfusion. and continuously recorded (MT95000, Astro-Med, West average age of 15 weeks (40.9 61.5 kg) were premediWarwick, RI,USA). All measurements were performed cated with 10 mg / kg azaperone IM, anesthetized with during sinus rhythm. When an animal presented any thiopental 30 mg / kg IV, intubated and mechanically arrhythmia at a time at which hemodynamic measurements ventilated with room air. A continuous infusion of thiopenwere scheduled, these measurements were performed at the tal was used to maintain anesthesia. The right femoral closest time point in which arrhythmias were absent. artery was catheterized with a 5F introducer and a catheter was advanced into the thoracic aorta. A midline ster-2.3. L-Arginine and cGMP concentrations notomy was performed and the pericardium was opened. The left anterior descending coronary artery (LAD) was Venous blood samples (5 ml) for L-arginine and cGMP dissected free at its midpoint and surrounded by an elastic determination were withdrawn prior to infusion of L-arsnare. As previously described [4] 2 pairs of 1-mm ginine or placebo, immediately before coronary occlusion, diameter ultrasonic crystals were inserted into the inner at 15 and 45 min of occlusion, and at 120 min of third of the left ventricle wall in the LAD and circumflex reperfusion. The samples were placed in an ice-filled tray territory respectively. The crystals of each pair were placed and plasma was obtained in the following 30 min. Lapproximately 1 cm apart, and were stimulated by a Arginine concentration was analyzed by reversed-phase R System 6 microsonometer (Triton Technology, San Diego, HPLC (Pico-Tag , Waters, MA, USA), after pre-column CA, USA) and monitored with an HM 205-3 oscilloscope derivatization with phenylisothyocyanate using UV de-(Hameg Instruments, Frankfurt Main, Germany). A prestection. cGMP concentration was measured by radioim-3 sure transducer catheter (Mikro-tip, Millar Instruments, munoassay using acetylated [ H]cGMP as previously TX, USA) was advanced into the left ventricle through a described [8] . Five additional animals were used to small puncture in the lateral free left ventricular wall, and a monitor cGMP concentration at the great coronary vein. transit time flow probe (T-106, Transonic Systems, NY, These animals were submitted to the same instrumentation USA) was placed around the dissected segment of the and study protocol and were randomly allocated to the LAD. Body core temperature was monitored and myocar-L-arginine (n53) or to the control groups (n52). In these dial temperature in the area at risk was continuously animals, a 5F multipurpose catheter (Cordis, Roden, The measured by means of an intramyocardial probe introduced Netherlands) was advanced through the right jugular vein at a depth of 5 mm into the ventricular wall at the center of into the great coronary vein as close as possible to the the LAD territory (Digi-Sense, Cole-Parmer Instrument, LAD occlusion site. Sequential aortic and coronary vein Illinois, USA).
blood samples were simultaneously obtained to monitor arteriovenous cGMP gradient in the LAD territory. Finally, Leica Instruments, Nussloch, Germany) and stained with myocardial cGMP content was measured in eight additionMasson's trichrome. The correlation between the negative al animals submitted to L-arginine or control group study reaction of TTC and the extent of contraction band protocols. In these animals, ventricular fibrillation was necrosis was analyzed in six randomly selected hearts induced after 10 min of reperfusion by application of an (three from each group) in which the extent of contraction epicardial DC current, and the apical third of the ventricles band necrosis was quantified morphometrically. An averwas sectioned with a dermatome blade and immersed in age of 167616 digital microphotographs of adjacent liquid nitrogen. The whole procedure lasted less than 3 s.
optical fields (X400) were blindly obtained from each slice Frozen myocardial fragments were obtained from reper-(DP10 Olympus microscope digital camera, resolution fused and control myocardium, pulverized under liquid 128031024 pixels, Tokyo, Japan) according to serial lines nitrogen, and homogenized using cold trichloroacetic acid irradiating from the center of the ventricular cavity and at 7.5% (weight / volume). cGMP concentration was meacovering the whole area at risk, as identified in the sured in the homogenates as previously described [7] .
corresponding fluorescent image. The extent of contraction band necrosis was calculated from the fraction involved in 2.4. Segment length measurements each image and compared with the extent of the area of negative TTC reaction in the myocardial slice. End-diastolic and end-systolic segment lengths (EDSL, ESSL), and maximal and minimal segment length were 2.7. Myeloperoxidase activity in myocardial tissue measured as previously described [4] . Systolic shortening was calculated as the ratio of the difference between EDSL MPO activity was determined in myocardial tissue as an and ESSL divided by EDSL. EDSL throughout the experiindex of PMN accumulation. Samples obtained from the ment was referred to its initial value before drug infusion.
area at risk and control zone of the third myocardial slice Amplitude of segment length change was calculated as the were stored at 2808C until processed for analysis. MPO difference between the maximal and the minimal values of activity was spectrophotometrically determined as previsegment length throughout a cardiac cycle [16] . The ously described by a modification of Bradley's method reduction in this amplitude was assumed to reflect an [16] (Reader 234 ATTC, SLT Labinstruments, Salzburg, increase in myocardial stiffness and used as an index of the Austria), and expressed in units defined as the quantity of development of rigor contracture [16] .
enzyme that was able to degrade 1 mmol / l / min of peroxide at 258C. 2.5. Post-mortem studies 2.8. Statistical analysis After 2 h of reperfusion, the LAD was re-occluded and 5 ml of 10% fluorescein was injected into the left atrium.
All measurements were performed by investigators blind The heart was excised, cooled at 48C, and cut into 5-7 mm to treatment allocation. Statistical analysis was performed slices. The third slice, starting from the apex, was prousing commercial available software (SPSS for Windows cessed for determination of myeloperoxidase (MPO) ac-7.0). The homogeneity between groups was tested by tivity. The rest of the slices were illuminated from the two-tail Student's t-test for independent samples. The basal side (the apical side of the forth slice was also hypothesis of a beneficial effect of L-arginine, established a imaged) with ultraviolet light to outline the area at risk, priory, and based on isolated myocytes and rat heart and digital images were obtained (Olympus Digital Castudies was tested by one-tail Student's t-test for mean mera C-1400L, Olympus Optical, Tokyo, Japan). The comparisons. Differences in cGMP content between conslices were then incubated at 378C for 10 min in 1% trol and reperfused myocardium in treated and control triphenyltetrazolium chloride (TTC) buffered at pH 7.4 animals were evaluated by means of the ANOVA test. and imaged again under white light with a reference scale.
Changes in segment length and physiologic parameters The area at risk and the area of necrosis were measured in were studied by means of the MANOVA test. A critical the digitized images using commercially available software P-value of 0.05 was used for all tests. All values are (MICROIMAGE, Olympus Optical, Hamburg, Germany). The expressed as mean6S.E.M. mass of myocardium at risk and of the necrotic myocardium were calculated from these measurements and from the weight of the slices.
Results

Histological analysis
In the series of 24 animals used for measurement of infarct size, one animal died due to intractable ventricular The second slice of each heart was fixed in 20% fibrillation and two presented reocclusion of the LAD formaldehyde and 4-mm thick sections including the whole during the reperfusion period. All the results are from the area at risk were obtained (Leica RM2145 microtome, remaining 21 animals, ten in the L-arginine group, and 11 
Plasma cGMP concentration
Plasma cGMP concentration was 37.867.2 pmol / ml at the beginning of the experiment, without differences small difference in heart rate that appeared between the between groups. Infusion of L-arginine had no effect on two groups after infusion of the solution containing the plasma cGMP which was similar in both groups at the allocated treatment persisted throughout the experiment, onset of coronary occlusion (37.166.9 and 35.969.7
and heart rate remained higher in the L-arginine group pmol / ml respectively, P50.92).
(11466 vs. 9866 at the onset of reperfusion, 11467 vs. 9567 after 5 min of reperfusion, and 11466 vs. 10064 3.2. Coronary occlusion and reperfusion after 2 h, P,0.05). Mean aortic pressure slightly increased in all animals (from 87.8616.3 mmHg before coronary 3.2.1. Hemodynamics occlusion to 96615 mmHg before reperfusion) and reChanges in heart rate during coronary occlusion and mained stable until the end of the experiment (100615.9 reperfusion were virtually identical in both groups. The mmHg), without differences between groups. Changes in LV pressure during ischemia-reperfusion were not different in both groups (Fig. 2 ).
Coronary blood flow
There were no differences between groups in coronary blood flow during reperfusion, although a non-significant trend was observed towards higher values in the L-arginine group (Fig. 3) .
Regional wall function
Changes in EDSL and systolic shortening during ischemia and reperfusion are represented in Fig. 4 . Coronary occlusion induced a rapid and marked increase in EDSL and abolition of systolic shortening identical in both reduction of EDSL that was much less pronounced and reversible in the L-arginine group than in controls (Fig. 4a) . After 30 min of reflow, EDSL was 107.863.2% in the L-arginine group vs. 98.063 in controls (P50.025), and this difference was maintained until the end of the experiment (109.063.5 vs. 100.362.1, P50.043). There was no significant recovery of contractile function during reperfusion, and systolic shortening remained close to 0% and nearly identical in the two groups until the end of the groups. After 5 min of ischemia, the change in segment length during the cardiac cycle in the ischemic area was assumed to be passive. All subsequent measurements of minutes of ischemia and then showed a progressive the amplitude of passive segment length change were reduction reflecting the development of rigor contracture normalized as a percentage of the value measured after 5 [16] . This reduction started 19.7611 min after coronary min of ischemia. In all animals, the normalized amplitude occlusion, without differences between groups. At the end of segment length change remained stable during the first of the coronary occlusion period, the amplitude of segment length change was 59.264.0% of that measured after 5 min of ischemia, without differences between groups. There were no differences in EDSL in the circumflex territory throughout the experiment between the L-arginine and control groups: 100. 
cGMP concentration
Plasma cGMP concentration was similar in both groups during ischemia. During reperfusion, however, there was a (18.161.6 and 19.062.1 g respectively, P50.76). Howtransient but significant increase in plasma cGMP in the ever, the mass of myocardial necrosis was smaller in L-arginine group compared to basal value (from 33.366.0 animals receiving L-arginine than in controls. Infarct size, to 62.9613.8 pmol / ml, P50.02) (Fig. 5) . In the additional defined as the percent of myocardium at risk developing five experiments in which it was measured, basal cGMP in necrosis, was significantly smaller in the L-arginine group the great cardiac vein was 27.866.4pmol / ml. Infusion of (Fig. 6 ). L-arginine was associated with a transient rise in coronary vein cGMP peaking at 10 min after the onset of reperfusion (166621% of baseline value) that was not observed in 3.2.7. Histology controls (122638%, P5NS). After 1 h of reperfusion, All infarcts were almost exclusively composed of concGMP concentration at the great coronary vein was traction band necrosis. In the six hearts in which quantita-93618% of basal value in the L-arginine group and tive histology was performed, contraction band necrosis 64619% in controls. Arteriovenous difference in cGMP involved 36611% of the area under examination, and TTC concentration, undetectable at baseline (2161 pmol / ml), reaction detected necrosis in 5169% of this area, with a showed a small increase immediately after infusion of close correlation between both measurements (r50.82, L-arginine (763 pmol / ml immediately before coronary P,0.05). occlusion, vs. 264 pmol / ml in controls). Arteriovenous difference after 1 min of reperfusion was 361 pmol / ml in the L-arginine group and 2163 pmol / ml in controls, and 3.2.8. Myeloperoxidase activity after 1 h of reperfusion, the differences were 262 and Myocardial MPO activity in control myocardium was 2465 pmol / ml respectively. In animals allocated to 10 0.4660.08 U / g. In reperfused myocardium, MPO content min of reperfusion, myocardial cGMP content was reduced was significantly higher without differences between Lin reperfused as compared to control myocardium, and was arginine and controls groups (1.1760.26 and 1.160.12 consistently higher in animals receiving L-arginine (Table  U / There were no significant changes in hematocrit, platelet control groups in the mass of myocardium at risk count, glucose, potassium, sodium or urea plasma concentrations throughout the experiment in any of the groups. Previous observations in the isolated rat heart perfused or time to peak electrical unstabilility, but was associated with crystalline, arginine-free media have shown that with attenuated myocardial segment shrinkage, an index of addition of L-arginine improves functional recovery after reperfusion-induced hypercontracture [17] , and with retransient ischemia [9, 24, 25] and reduces reperfusion arduced extent of contraction band necrosis, the pathological rhythmias [31] . The effect of L-arginine during in vivo correlate of hypercontracture. These results are consistent ischemia-reperfusion has been less investigated, and has with previous observations indicating that L-arginine supyielded more controversial results, probably due, to a large plementation protects cardiomyocytes against reperfusionextent, to differences in models (hypoxia, sublethal isinduced hypercontracture.
chemia, prolonged ischemia), doses and time of L-arginine administration, and end-points analyzed. L-Arginine was 4.1. NO kinetics in reperfused myocardium found to adversely influence postischemic or posthypoxic functional recovery in the pig and dog models [23, 32] . Endothelial cells are the main source of NO in myocarSystemic administration of L-arginine after the onset of dial tissue under normal conditions. Endothelial NO is ischemia failed to reduce infarct size in pigs submitted to essential for normal cardiac perfusion and function. NO, 45 min of coronary occlusion and reperfusion [33] . In through stimulation of cGMP synthesis in target cells, contrast, intracoronary infusion of L-arginine during reinhibits the adhesion of platelets and leukocytes to the perfusion reduced myocardial PMN accumulation and endothelial surface, relaxes adjacent smooth muscle cells, necrosis in dogs submitted to 60 min of coronary occlusion and modulates cardiomyocyte contraction [18, 19] . Howand 270 min of reperfusion [14] . A reduction in infarct size ever, excessive NO concentration may be harmful either by and myocardial MPO content was found in cats submitted direct reaction with cell proteins or DNA, or through to 90 min of coronary and 6 h of reperfusion that had highly reactive species produced by the reaction of NO However, D-arginine could have significant cardiovascular in production of large amounts of NO [21, 22] . However, effects [33, 34] and cannot be considered an adequate most studies suggest that NO availability is reduced in control for all possible effects of L-arginine. The present myocardium reperfused after prolonged ischemia [8,12,23- study confirms the beneficial effect of systemic administra-25]. The contributions of reduced synthesis and increased tion of L-arginine on reperfusion injury, and extend rate of reaction with O to this reduction have not been previous results in demonstrating that this effect can be 2 established. A large number of studies have shown that achieved with lower doses which are within clinical range, administration of NO donors and manoeuvers increasing and that it is not dependent on increased coronary blood myocardial NO availability during early reperfusion imflow or reduced PMN-mediated reperfusion injury. prove post-ischemic functional recovery [14, 26, 27] , and reduce cell necrosis in reperfused myocardium 4.3. Mechanism of protection [8, 12, 13, 25] .
L-Arginine is the only known substrate for NO synthesis The results of the present study support the hypothesis in vivo. Under normal conditions the concentration of that the increase in NO availability and cGMP synthesis L-arginine in endothelial cells is well over the level caused by L-arginine protects cardiomyocytes against necessary to saturate NOS. However, there is ample reperfusion-induced hypercontracture. It has been shown evidence that increasing plasma L-arginine concentration that cGMP concentration is reduced in reperfused or enhances NO synthesis [28, 29] , a phenomenon termed reoxygenated myocardium [5, 8] , and that this reduction is 'L-arginine paradox'. During ischemia and reperfusion the attenuated or reversed by the administration of L-arginine increase in NO synthesis induced by L-arginine administra- [5, 8, 9] . In the present study, animals receiving L-arginine tion is easier to understand. Under these conditions, showed a significant increase in great coronary vein and reduced ATP-dependent L-arginine transport or regeneraarterial cGMP concentration during the early phase of tion from L-citrulline may impair NO synthesis [10, 30] . On reperfusion. Our results do not allow the determination of the possible contribution of extra-myocardial sources of mentation could have an additional and potentially relevant cGMP release to the observed increase in arterial cGMP beneficial effect in patients with atherosclerosis. New concentration. However, the results of measurement of studies are clearly needed to define the therapeutic value of myocardial cGMP content in seven additional animals are this effect. fully consistent with our working hypothesis. Measurement of myocardial cGMP content had to be performed in an additional series of experiments since this measurement
